Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumors

Carcinogenesis

Volumn 25, Issue 10, 2004, Pages 1917-1923

  Pereira, Michael A ^a   Tao, Lianhui ^a   Wang, Wei ^a   Li, Yingzhe ^a   Umar, Asad ^b   Steele, Vernon E ^b   Lubet, Ronald A ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BIOLOGICAL MARKER; CELECOXIB; DNA; EFLORNITHINE; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; CPG ISLAND; DEATH; DIET; DNA METHYLATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; EXON; GENE EXPRESSION; HYPOTHESIS; MALE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZOXYMETHANE; CARCINOGENS; COLON; COLONIC NEOPLASMS; CPG ISLANDS; DIET; DNA METHYLATION; EFLORNITHINE; ESTROGEN RECEPTOR ALPHA; MALE; PYRAZOLES; RATS; RATS, INBRED F344; RECEPTORS, ESTROGEN; RNA, MESSENGER; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 6444226573     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh209     Document Type: Article

References (34)

1. Greelee,R.T., Hill-Harman,M.B., Murray,T. and Thun,M. (2001) Cancer statistics. CA Cancer J. Clin., 51, 15-27.
2. Krishnan,K., Ruffin,I.V.M.T. and Brenner,D.E. (2000) Chemoprevention for colorectal cancer. Crit. Rev. Oncol. Hematol., 33, 199-219.
3. Kelloff,G.J., Sigman,C.C., Hawk,E.T., Johnson,K.M., Crowell,J.A. and Guyton,K.Z. (2001) Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci. Publ., 154, 13-26.
4. Sivastavav,S., Verma,M. and Henson,D.E. (2001) Biomarkers for early detection of colon cancer. Clin. Cancer Res., 7, 1118-1126.
5. Zingg,J.M. and Jones,P.A. (1997) Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis, 18, 869-882.
6. Baylin,S.B., Herman,J.G., Graff,J.R., Vertino,P.M. and Issa,J.P. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72, 141-196.
7. Goelz,S.E., Vogelstein,B., Hamilton,S.R. and Fiering,A.P. (1985) Hypomethylation of DNA from benign and malignant human colon neoplasms. Science, 228, 197-190.
8. Feinberg,A.P., Gehrke,C.W., Jui,K.C. and Ehrlich,M. (1988) Reduced genomic 5-methylcystosine content in human colonic neoplasia. Cancer Res., 48, 1159-1161.
9. Lengauer,C., Kinzler,K.W. and Vogelstein,B. (1997) DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl Acad. Sci. USA, 94, 2545-2550.
10. Dunn,B.K. (2003) Hypomethylation: one side of a larger picture. Ann. N. Y. Acad. Sci., 983, 28-42.
11. Chen,H., Tini,M. and Evans,R.M. (2001) HATs on and beyond chromatin. Curr. Opin. Cell Biol., 13, 218-224.
12. Reid,G., Denger,S., Kos,M. and Gannon,F. (2002) Human estrogen receptor-α: regulation by synthesis, modification and degradation. Cell Mol. Life Sci., 59, 821-831.
13. Issa,J.P., Ottaviano,Y.L., Celano,P., Hamilton,S.R., Davidson,N.E. and Baylin,S.B. (1994) Methylation of the oestrogen rececptor CpG island links ageing and neoplasma in human colon. Nature Genet., 7, 536-540.
14. Ahuja,N., Li,Q., Mohan,A.L., Baylin,S.B. and Issa,J.P. (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 8, 5489-5494.
15. Issa,J.P. (1999) Aging, DNA methylation and cancer. Crit. Rev. Oncol. Hematol., 32, 31-43.
16. Kondo,Y. and Issa,J.P. (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev., 23, 29-39.
17. Issa,P.J., Ahuja,N., Toyota,M., Bronner,P. and Brentnall,T.A. (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res., 61, 3573-3577.
18. Steele,V.E., Moon,R.C., Lubet,R.A. et al. (1994) Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J. Cell Biochem., (suppl. 20), 32-54.
19. Bird,R.P. (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett., 93, 55-71.
20. Kawamori,T., Rao,C.V., Seibert,K. and Reddy,B.S. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409-412.
21. Rao,C.V., Indranie,C., Simi,B., Manning,P.T., Connor,J.R. and Reddy,B.S. (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62, 165-170.
22. Yamada,Y., Yoshimi,N., Hirose,Y. and Hara,A. (2001) Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn. J. Cancer Res., 92 617-623.
23. Reddy,B.S., Hirose,Y., Lubet,R. and Steele,V. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 60, 293-297.
24. Li,H., Schut,H.A.J., Conran,P., Kramer,P.M., Lubet,R.A., Steele,V.E., Kelloff,G.J. and Pereira,M.A. (1999) Prevention by aspirin and its combination with difluoromethylornithine of azoxymethane-induced tumors and aberrant crypt foci in the colon of rats. Carcinogenesis 20, 425-430.
25. Tao,L., Kramer,P.M., Wang,W., Yang,S., Lubet,R.A., Steele,V.E. and Pereira,M.A. (2002) Altered expression of c-myc, P16 and P27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis, 23, 1447-1454.
26. Reddy,B.S., Nayini,J., Tokumo,K., Rigotty,J., Zang,E. and Kelloff,G. (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res., 50, 2562-2568.
27. Tao,L., Li,Y., Wang,W., Kramer,P.M., Gunning,W.T., Lubet,R.A., Steele,V.E. and Pereira,M.A. (2002) Effect of budesonide on the methylation and mRNA expression of the IGF-II and c-myc genes in mouse lung tumors. Mol. Carcinogen., 35, 93-102.
28. Tao,L., Wang,W., Kramer,P.M., Lubet,R.A., Steele,V.E. and Pereira,M.A. (2004) Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol. Carcinogen., 39, 79-84.
29. Foley,E.F., Jazaeri,A.A., Shupnik,M.A., Jazaeri,O. and Rice,L.W. (2000) Selective loss of estrogen receptor β in malignant human colon. Cancer Res., 60, 245-248.
30. Campbell-Thompson,M., Lynch,I.J. and Bhardwaj,B. (2001) Expression of estrogen receptor (ER) subtypes and ER β isoforms in colon cancer. Cancer Res., 61, 632-640.
31. Qui,Y., Waters,C.E., Lewis,A.E., Langman,M.J. and Eggo,M.C. (2002) Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J. Endocrinol., 174, 369-377.
32. Jacoby,R.F., Cole,C.E., Tutsch,K. and Newton,M.A. (2000) Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas and selective toxicity against Apc mutant embryos. Cancer Res., 60 1864-1870.
33. Fischer,S.M., Conti,C.J., Viner,J., Aldaz,C.M. and Lubet,R.A. (2003) Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis, 24, 945-952.
34. Fernandez,P.C., Frank,S.R., Wang,L., Schroeder,M., Liu,S., Greene,J., Cocito,A. and Amati,B. (2003) Genomic targets of the human c-Myc protein. Genes Der., 17, 1115-1129.